[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600566":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":83,"collaborators":87,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":11,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":11,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Brivudine Group","EXPERIMENTAL",null,[13],"Drug: Brivudine",{"label":15,"type":16,"description":11,"interventionNames":17},"Famciclovir Group","ACTIVE_COMPARATOR",[18],"Drug: Famciclovir",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Brivudine","brivudine 125 mg per dose, once daily, 7 days",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Famciclovir","orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Jin-Zhu Guo, M.D.","CONTACT","008613521115717","guojinzhu_826@163.com",[36,52,62,72],{"facility":5,"status":37,"city":38,"state":11,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","100191","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":51,"phoneExt":11,"email":34},"Jinzhu Guo, M.D.","008615611963350",{"facility":53,"status":37,"city":38,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Beijing Hospital of Traditional Chinese Medicine, Capital Medical University",{"type":43,"coordinates":55},[45,46],{"lat":46,"lon":45},[58],{"name":59,"role":32,"phone":60,"phoneExt":11,"email":61},"Dongmei Zhou, M.D.","008613811201580","52176857@163.com",{"facility":63,"status":37,"city":38,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Peking University First Hospital",{"type":43,"coordinates":65},[45,46],{"lat":46,"lon":45},[68],{"name":69,"role":32,"phone":70,"phoneExt":11,"email":71},"Xiaowen Wang, M.D.","008615901254602","xiaowenpku@126.com",{"facility":73,"status":74,"city":38,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Xuanwu Hospital, Capital Medical University","NOT_YET_RECRUITING",{"type":43,"coordinates":76},[45,46],{"lat":46,"lon":45},[79],{"name":80,"role":32,"phone":81,"phoneExt":11,"email":82},"Haiping Zhang, M.D.","008613701205765","zhanghaiping@xwhosp.org",{"type":84,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Guo Jin-Zhu","Deputy Director of Dermatology",[88,89,91,93],{"name":63,"class":6},{"name":90,"class":6},"Air Force Military Medical University, China",{"name":92,"class":6},"Beijing Hospital of Traditional Chinese Medicine",{"name":94,"class":6},"Xuanwu Hospital, Beijing","100600566","phase-4-efficacy-and-safety-of-brivudine-in-the-treatment-of-herpes-zoster-100600566",false,"NCT07099157","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Signed Informed Consent Form;\n3. Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:\n\n   * Barrier methods: Condom or barrier cap (diaphragm or cervical cap);\n   * Intrauterine device (IUD) or intrauterine system (IUS);\n   * Surgical sterilization (bilateral oophorectomy with\u002Fwithout hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;\n   * Other investigator-confirmed highly effective physical contraception.\n\nExclusion Criteria:\n\n1. Allergy to brivudine, famciclovir, or penciclovir;\n2. Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);\n3. Cancer patients currently undergoing chemotherapy;\n4. Pregnant or lactating women;\n5. Parkinson's disease;\n6. Any condition deemed inappropriate for study participation by the investigator.","ALL","18 Years",{"count":105,"type":106},140,"ESTIMATED","INTERVENTIONAL",[109],"PHASE4","This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3\u002FDay 7\u002FDay 14\u002FDay 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.",[112],"Herpes Zoster",[112,22,114,115],"pain","treatment","2025-12-28",{"date":118,"type":119},"2026-01-02","ACTUAL",{"date":121,"type":119},"2025-08-25",{"date":123,"type":106},"2027-12-31",{"name":5,"class":6},4]